Genocea Biosciences (GNCA) Tops Q1 EPS by 3c

Genocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.17), $0.03 better than the analyst estimate of ($0.20).

“Genocea continues to accumulate evidence that our ATLAS™ platform may enable immunotherapies that preferentially attack the surface-presented antigens driving anti-tumor responses or as we say, ‘Targets Matter’,” said Chip Clark, Genocea’s President and Chief Executive Officer. “Whether through our ongoing clinical trials with GEN-011, our neoantigen-targeted peripheral T cell (“NPT”) therapy and GEN-009, our neoantigen vaccine, or through our research efforts with Inhibigens™ and SARS-CoV-2 antigen discovery, we look forward to providing updates consistent with this thesis throughout the year.”

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Faeth Therapeutics names two SVPs ahead of clinical milestones
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c